Background:Eggerthella lenta is an anaerobic gram-positive bacillus associated with severe bloodstream infections and high mortality rates.However,limited antimicrobial susceptibility data in China hinder effective cl...Background:Eggerthella lenta is an anaerobic gram-positive bacillus associated with severe bloodstream infections and high mortality rates.However,limited antimicrobial susceptibility data in China hinder effective clinical treatment.We aimed to address this by analyzing the antimicrobial susceptibility profiles of E.lenta strains isolated from bloodstream and abdominal fluid infections to provide evidence-based guidance for empirical treatment in clinical practice.Methods:This study reviewed 36 cases of E.lenta isolated and cultured from bloodstream and abdominal fluids between 2018 and 2024.The isolates were identified using various methods,including the VITEK 2 ANC card,MALDI-TOF mass spectrometry,and a 16S rRNA gene sequencing assay.Antimicrobial drug susceptibility testing of the 36 E.lenta isolates was conducted using the agar dilution method.A minimum inhibitory concentration(MIC)fold analysis was performed with reference to the CLSI and EUCAST guidelines.Results:The identification of E.lenta was performed using VITEK-2,MALDI-TOF MS,and 16S rRNA sequencing.All methods showed high consistency,with 16S rRNA sequencing confirming the species classification of the isolates.Eggerthella lenta exhibited varying degrees of resistance to penicillin,ampicillin,ceftriaxone,levofloxacin,clindamycin,ceftazidime,imipenem,piperacillin-tazobactam,and amikacin.Conversely,the bacterium was sensitive to amoxicillin-clavulanic acid,moxifloxacin,chloramphenicol,metronidazole,and vancomycin.Conclusions:These findings indicate that metronidazole,amoxicillin-clavulanic acid,moxifloxacin,and vancomycin are the preferred empirical treatments for E.lenta.Furthermore,there is an urgent need to optimize anti-E.lenta treatment guidelines and the MIC threshold values for piperacillin-tazobactam to ensure a close correlation with clinical data and to accurately guide the effective management of invasive E.lenta infections.展开更多
基金supported by Chongqing Technology Innovation and Application Development Special General Project,Grant/Award Number:2023TIAD‐GPX0126Chongqing Medical Scientific Research Project(Joint Project of Chongqing Health Commission and Science and Technology Bureau),Grant/Award Number:2025MSXM004+1 种基金Key Project of Science and Technology Research by Chongqing Municipal Education Commission,Grant/Award Numbers:KJZD‐K202400102 and KJZD‐K202400103Medical Research Project of Chongqing Municipal Health Commission,Grant/Award Number:2024WSJK007.
文摘Background:Eggerthella lenta is an anaerobic gram-positive bacillus associated with severe bloodstream infections and high mortality rates.However,limited antimicrobial susceptibility data in China hinder effective clinical treatment.We aimed to address this by analyzing the antimicrobial susceptibility profiles of E.lenta strains isolated from bloodstream and abdominal fluid infections to provide evidence-based guidance for empirical treatment in clinical practice.Methods:This study reviewed 36 cases of E.lenta isolated and cultured from bloodstream and abdominal fluids between 2018 and 2024.The isolates were identified using various methods,including the VITEK 2 ANC card,MALDI-TOF mass spectrometry,and a 16S rRNA gene sequencing assay.Antimicrobial drug susceptibility testing of the 36 E.lenta isolates was conducted using the agar dilution method.A minimum inhibitory concentration(MIC)fold analysis was performed with reference to the CLSI and EUCAST guidelines.Results:The identification of E.lenta was performed using VITEK-2,MALDI-TOF MS,and 16S rRNA sequencing.All methods showed high consistency,with 16S rRNA sequencing confirming the species classification of the isolates.Eggerthella lenta exhibited varying degrees of resistance to penicillin,ampicillin,ceftriaxone,levofloxacin,clindamycin,ceftazidime,imipenem,piperacillin-tazobactam,and amikacin.Conversely,the bacterium was sensitive to amoxicillin-clavulanic acid,moxifloxacin,chloramphenicol,metronidazole,and vancomycin.Conclusions:These findings indicate that metronidazole,amoxicillin-clavulanic acid,moxifloxacin,and vancomycin are the preferred empirical treatments for E.lenta.Furthermore,there is an urgent need to optimize anti-E.lenta treatment guidelines and the MIC threshold values for piperacillin-tazobactam to ensure a close correlation with clinical data and to accurately guide the effective management of invasive E.lenta infections.
